[1]
Beuvon C, Martin M, Baillou C, Roblot P, Puyade M. Etiologies of Polyclonal Hypergammaglobulinemia: A scoping review. European journal of internal medicine. 2021 Aug:90():119-121. doi: 10.1016/j.ejim.2021.05.023. Epub 2021 Jun 11
[PubMed PMID: 34127335]
Level 2 (mid-level) evidence
[2]
Dispenzieri A, Gertz MA, Therneau TM, Kyle RA. Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clinic proceedings. 2001 May:76(5):476-87
[PubMed PMID: 11357794]
Level 2 (mid-level) evidence
[3]
Chen LYC, Mattman A, Seidman MA, Carruthers MN. IgG4-related disease: what a hematologist needs to know. Haematologica. 2019 Mar:104(3):444-455. doi: 10.3324/haematol.2018.205526. Epub 2019 Jan 31
[PubMed PMID: 30705099]
[4]
Zhao EJ, Cheng CV, Mattman A, Chen LYC. Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management. The Lancet. Haematology. 2021 May:8(5):e365-e375. doi: 10.1016/S2352-3026(21)00056-9. Epub
[PubMed PMID: 33894171]
[5]
Buadi F, Hsing AW, Katzmann JA, Pfeiffer RM, Waxman A, Yeboah ED, Biritwum RB, Tettey Y, Adjei A, Chu LW, DeMarzo A, Netto GJ, Dispenzieri A, Kyle RA, Rajkumar SV, Landgren O. High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, Africa. American journal of hematology. 2011 Jul:86(7):554-8. doi: 10.1002/ajh.22040. Epub 2011 Jun 14
[PubMed PMID: 21674575]
[6]
Hirano T, Kishimoto T. Interleukin 6 and plasma cell neoplasias. Progress in growth factor research. 1989:1(3):133-42
[PubMed PMID: 2491260]
[7]
Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis research & therapy. 2006:8 Suppl 2(Suppl 2):S2
[PubMed PMID: 16899106]
[8]
Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. The Journal of clinical investigation. 1990 Aug:86(2):592-9
[PubMed PMID: 2384605]
[9]
van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. The Lancet. Oncology. 2014 Aug:15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17
[PubMed PMID: 25042199]
Level 1 (high-level) evidence
[10]
Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008 Nov 15:112(10):3959-64. doi: 10.1182/blood-2008-05-155846. Epub 2008 Sep 10
[PubMed PMID: 18784373]
[11]
Saiki R, Katayama K, Hirabayashi Y, Oda K, Fujimoto M, Murata T, Nakajima A, Dohi K. Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature. BMC nephrology. 2021 Jun 9:22(1):216. doi: 10.1186/s12882-021-02423-w. Epub 2021 Jun 9
[PubMed PMID: 34107915]
Level 3 (low-level) evidence
[12]
Del Giudice M, Gangestad SW. Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. Brain, behavior, and immunity. 2018 May:70():61-75. doi: 10.1016/j.bbi.2018.02.013. Epub 2018 Mar 1
[PubMed PMID: 29499302]
[13]
Thomas HC, McSween RN, White RG. Role of the liver in controlling the immunogenicity of commensal bacteria in the gut. Lancet (London, England). 1973 Jun 9:1(7815):1288-91
[PubMed PMID: 4126078]
[14]
Hunninghake GW, Crystal RG. Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. The Journal of clinical investigation. 1981 Jan:67(1):86-92
[PubMed PMID: 6969734]
[15]
Huang L, Li CJ, Pardee AB. Human immunodeficiency virus type 1 TAT protein activates B lymphocytes. Biochemical and biophysical research communications. 1997 Aug 18:237(2):461-4
[PubMed PMID: 9268734]
[16]
Raj S, Guha B, Rodriguez C, Krishnaswamy G. Paraproteinemia and serum protein electrophoresis interpretation. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2019 Jan:122(1):11-16. doi: 10.1016/j.anai.2018.08.004. Epub
[PubMed PMID: 30579431]
[17]
Ochs HD. Patients with abnormal IgM levels: assessment, clinical interpretation, and treatment. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2008 May:100(5):509-11. doi: 10.1016/S1081-1206(10)60479-6. Epub
[PubMed PMID: 18517086]
[18]
Notarangelo LD,Duse M,Ugazio AG, Immunodeficiency with hyper-IgM (HIM). Immunodeficiency reviews. 1992;
[PubMed PMID: 1554497]
[19]
Yazdani R,Fekrvand S,Shahkarami S,Azizi G,Moazzami B,Abolhassani H,Aghamohammadi A, The hyper IgM syndromes: Epidemiology, pathogenesis, clinical manifestations, diagnosis and management. Clinical immunology (Orlando, Fla.). 2019 Jan;
[PubMed PMID: 30439505]
[20]
Haas D, Hoffmann GF. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet journal of rare diseases. 2006 Apr 26:1():13
[PubMed PMID: 16722536]
[21]
Hasan Ali O, Bomze D, Risch L, Brugger SD, Paprotny M, Weber M, Thiel S, Kern L, Albrich WC, Kohler P, Kahlert CR, Vernazza P, Bühler PK, Schüpbach RA, Gómez-Mejia A, Popa AM, Bergthaler A, Penninger JM, Flatz L. Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 Nov 2:73(9):e2869-e2874. doi: 10.1093/cid/ciaa1496. Epub
[PubMed PMID: 32997739]
[22]
Woellner C, Gertz EM, Schäffer AA, Lagos M, Perro M, Glocker EO, Pietrogrande MC, Cossu F, Franco JL, Matamoros N, Pietrucha B, Heropolitańska-Pliszka E, Yeganeh M, Moin M, Español T, Ehl S, Gennery AR, Abinun M, Breborowicz A, Niehues T, Kilic SS, Junker A, Turvey SE, Plebani A, Sánchez B, Garty BZ, Pignata C, Cancrini C, Litzman J, Sanal O, Baumann U, Bacchetta R, Hsu AP, Davis JN, Hammarström L, Davies EG, Eren E, Arkwright PD, Moilanen JS, Viemann D, Khan S, Maródi L, Cant AJ, Freeman AF, Puck JM, Holland SM, Grimbacher B. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. The Journal of allergy and clinical immunology. 2010 Feb:125(2):424-432.e8. doi: 10.1016/j.jaci.2009.10.059. Epub
[PubMed PMID: 20159255]
[23]
Sarnat RL, Jampol LM. Hyperviscosity retinopathy secondary to polyclonal gammopathy in a patient with rheumatoid arthritis. Ophthalmology. 1986 Jan:93(1):124-7
[PubMed PMID: 3951809]
[24]
Gertz MA. Acute hyperviscosity: syndromes and management. Blood. 2018 Sep 27:132(13):1379-1385. doi: 10.1182/blood-2018-06-846816. Epub 2018 Aug 13
[PubMed PMID: 30104220]
[25]
Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH. Rituximab for IgG4-related disease: a prospective, open-label trial. Annals of the rheumatic diseases. 2015 Jun:74(6):1171-7. doi: 10.1136/annrheumdis-2014-206605. Epub 2015 Feb 9
[PubMed PMID: 25667206]
[26]
Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4 related disease. BMJ (Clinical research ed.). 2020 Jun 16:369():m1067. doi: 10.1136/bmj.m1067. Epub 2020 Jun 16
[PubMed PMID: 32546500]
Level 3 (low-level) evidence
[27]
Wong PC,Fung AT,Gerrie AS,Moloney G,Maberley D,Rossman D,White V,Collins D,Coupland R,Chen LY, IgG4-related disease with hypergammaglobulinemic hyperviscosity and retinopathy. European journal of haematology. 2013 Mar
[PubMed PMID: 23278107]
[28]
Vladutiu AO,Roach BM,Farahmand SM, Polyclonal gammopathy with marked increase in serum viscosity. Clinical chemistry. 1991 Oct;
[PubMed PMID: 1914185]
[29]
Funada M, Nakano K, Miyata H, Nawata A, Tanaka Y. IgG4-type Multiple Myeloma with Diffuse Enlargement of the Thyroid Requiring Differentiation from IgG4-related Disease. Internal medicine (Tokyo, Japan). 2020:59(5):711-714. doi: 10.2169/internalmedicine.3839-19. Epub
[PubMed PMID: 32115519]
[30]
Tang SH,Lin MH,Du JS,Liu YC,Hsiao HH,Liu TC, IgG4-related disease with bone marrow involvement mimicking multiple myeloma. British journal of haematology. 2017 Jun;
[PubMed PMID: 28439907]
[31]
Finn WG, Gulbranson R, Fisher S, Rae Sample L, Shalhoub R, Hedstrom D, Keren DF. Detection of Polyclonal Increases in Immunoglobulin G4 Subclass by Distinct Patterns on Capillary Serum Protein Electrophoresis: Diagnostic Pitfalls and Clinical Observations in a Study of 303 Cases. American journal of clinical pathology. 2016 Sep:146(3):303-11. doi: 10.1093/ajcp/aqw113. Epub 2016 Jul 31
[PubMed PMID: 27477045]
Level 3 (low-level) evidence
[32]
Banday AZ, Nataraj L, Jindal AK, Kaur H, Gummadi A, Sharma M, Pandiarajan V, Rawat A. False-positive HIV serology, Candida lusitaniae pneumonia, and a novel mutation in the CYBB gene. Immunobiology. 2021 Jul:226(4):152110. doi: 10.1016/j.imbio.2021.152110. Epub 2021 Jul 2
[PubMed PMID: 34242877]
[33]
Qujeq D,Mohiti J, Decreased anion gap in polyclonal hypergammaglobulinemia. Clinical biochemistry. 2002 Feb;
[PubMed PMID: 11937082]
[34]
Fabijańska-Mitek J, Zupańska B, Pogłód R, Gorajek M, Lopieńska H, Kraj M. Evaluation of the microcolumn technology for pretransfusion testing in multiple myeloma patients. Vox sanguinis. 1998:74(1):31-5
[PubMed PMID: 9481858]